Seminars in Hematology
Volume 40, Issue 1 , Pages 22-33 , January 2003

Interferon-alfa for chronic myeloid leukemia

References 

  1. Allan NC, Richards SM, Shepherd PCA, et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392–1397
  2. Andrews DF, Singer JW, Collins SJ. Effects of recombinant α-Interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines. Cancer Res. 1987;47:6629–6632
  3. Arcese W, Goldman JM, Schattenberg A, et al.  Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood. 1993;82:3211–3219
  4. Archimbaud E, Michalet M, Philip I, et al.  Granulocyte colony-stimulating factor given in addition to interferon-α to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol. 1997;99:678–684
  5. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al.  ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 1999;94:2452–2460
  6. Baccarani M, Rosti G, de Vivo A, et al.  A randomized study of interferon-α versus interferon-α and low dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–1535
  7. Barthe C, Mahon FX, Gharbi MJ, et al.  Expression of interferon-α (IFN-α) receptor 2c at diagnosis is associated with cytogenetic response in IFN-α-treated chronic myeloid leukemia. Blood. 2001;97:3568–3573
  8. Benelux CML, Study Group . Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood. 1998;91:2713–2721
  9. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by marrow microenvironment in chronic myelogenous leukemia. Blood. 1996;87:3883–3891
  10. Beelen DW, Graeven U, Elmaagacli AH, et al.  Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981–2990
  11. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-α (IFN-α) on transplant outcome after marrow transplantation for chronic phase chronic myelogenous leukemia increases with the duration of IFN-α exposure. Blood. 1999;93:1996–1997 (letter)
  12. Ben-Yehuda D, Krichevsky S, Rachmilewtz EA, et al.  Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 1997;90:4918–4923
  13. Bonifazi F, de Vivo A, Rosti G, et al.  Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders. Blood. 2001;98:3074–3081
  14. Carella AM, Frassoni F, Melo J, et al.  New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 1997;82:478–495
  15. Carella AM, Lerma E, Corsetti MT, et al.  Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor in chronic myelogenous leukemia. Blood. 1999;93:1534–1539
  16. Chomel JC, Brizard F, Veinstein A, et al.  Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation. Blood. 2000;95:404–409
  17. Cohen N, Rozenfeld-Granot G, Hardan I, et al.  Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by deletion of 9q proximal to ABL gene: Expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet. 2001;128:114–119
  18. Chronic Myeloid Leukemia Trialists Collaborative Group . Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616–1620
  19. Cortes I, Fayad L, O'Brien S, et al.  Association of HLA phenotype and response to interferon-α in patients with chronic myelogenous leukemia. Leukemia. 1998;12:455–462
  20. Deng M, Daley GQ. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 2001;97:3491–3497
  21. Dowding C, Guo AP, Osterholz J, et al.  Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood. 1991;78:499–505
  22. Faderl SF, Talpaz M, Kantarjian HM, et al.  Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?. Blood. 1999;93:2755–2759
  23. Faderl L, Talpaz M, Kantarjian H, et al.  Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?. Blood. 1999;94:1487–1488 (letter)
  24. Frassoni F, Podesta M, Piaggio G, et al.  Normal primitive hematopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukemia but rapidly decline with time. Br J Haematol. 1999;104:568–578
  25. German and Italian Chronic Myeloid Leukaemia Study Groups Writing Committee . Interferon-α and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-α. Blood. 1996;87:5384–5391
  26. Giralt SA, Kantarjian HM, Talpaz M, et al.  Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055–1061
  27. Giralt S, Szydlo R, Goldman JM, et al.  Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the International Bone Marrow Transplant Registry. Blood. 2000;95:410–415
  28. Goldman JM. Management of chronic myeloid leukemia. Blood Rev. 1994;8:21–29
  29. Goldman JM, Kaeda J, Cross NCP, et al.  Clinical decision making in chronic myeloid leukemia based on polymerase chain rection analysis of minimal residual disease. Blood. 1999;94:1484–1486 (letter)
  30. Goldman JM, Druker BJ. Chronic myeloid leukemia: Current treatment options. Blood. 2001;98:2039–2042
  31. Guarini A, Breccia M, Montefusco E, et al.  Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol. 2001;113:136–142
  32. Guilhot F, Dreyfus B, Brizard A, et al.  Cytogenetic remission in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leuk Lymph. 1991;4:49–55
  33. Guilhot F, Chastang C, Michallet M, et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229
  34. Hasford J, Pfirrmann M, Hehlmann R, et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850–858
  35. Hehlmann R, Heimpel H, Hasford J, et al.  Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064–4077
  36. Hehlmann R, Ansari H, Hasford J, et al.  Comparative analysis of the impact of the risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol. 1997;97:76–85
  37. Hehlmann R, Hochhaus A, Kolb HJ, et al.  Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668–3677
  38. Higano CS, Chielens D, Raskind W, et al.  Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 1997;90:2549–2554
  39. Hochhaus A, Yan XH, Willer A, et al.  Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukemia. Leukemia. 1997;11:933–939
  40. Hochhaus A, Reiter A, Saubele S, et al.  Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62–66
  41. Huntly BJP, Reid AG, Bench AJ, et al.  Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001;98:1732–1738
  42. Issa JPJ, Kantarjian H, Mohan A, et al.  Methylation of the ABL1 promoter in chronic myelogenous leukemia; lack of prognostic significance. Blood. 1999;93:2075–2082
  43. Italian Cooperative Study Group on Chronic Myeloid Leukemia . A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica. 1992;77:204–214
  44. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  45. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Chronic myeloid leukemia, BCR/ABL transcript, response to α-interferon and survival. Leukemia. 1995;9:1648–1652
  46. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541–1548
  47. Italian Cooperative Study Group on Chronic Myeloid Leukemia . A prospective study of α-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. Haematologica. 1999;84:707–715
  48. Italian Cooperative Study Group on Chronic Myeloid Leukemia and GITMO . Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999;17:1858–1868
  49. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Testing Sokal's and the new prognostic score for chronic myeloid leukemia treated with α-interferon. Br J Haematol. 2000;111:587–595
  50. Italian Cooperative Study Group on Chronic Myeloid Leukemia: A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia (in press)
  51. Kantarjian HM, Talpaz M, Keating MJ, et al.  Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 1991;68:1201–1207
  52. Kantarjian HM, Smith TL, O'Brien S, et al.  Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254–261
  53. Kantarjian HM, O'Brien S, Smith TL, et al.  Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;117:284–292
  54. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: Long-term follow-up of 71 patients observed in a single center. Leukemia. 2000;14:389–392
  55. Landolfo S, Guarini A, Riera L, et al.  Chronic myeloid leukemia cells resistant to interferon-α lack STAT1 expression. Haematol J. 2000;1:7–14
  56. Lee SJ, Klein JP, Anasetti C, et al.  The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001;98:3205–3211
  57. Lindauer M, Domkin D, Döhner H, et al.  Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukemia. Br J Haematol. 1999;106:1013–1019
  58. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999;94:1486; (letter)
  59. Mahon FX, Fabères C, Pueyo S, et al.  Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-α. Blood. 1998;92:4059–4065
  60. Maloisel F, Guerci A, Guyotat D, et al.  Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002;16:573–580
  61. Martinelli G, Testoni N, Amabile M, et al.  Quantification of BCR-ABL transcript in CML patients in cytogenetic remission after interferon-α-based therapy. Bone Marrow Transplant. 2000;25:729–736
  62. McGlave PB, De Fabritiis P, Deisseroth A, et al.  Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet. 1994;34:1486–1488
  63. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood. 1991;78:1155–1161
  64. Montastruc M, Mahon FX, Fabères C, et al.  Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors. Leukemia. 1995;9:1997–2002
  65. Morton AJ, Gooley T, Hansen JA, et al.  Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation of chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394–401
  66. Müller CA, Walz J, Zinser R, et al.  In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFNα treatment. Ann Hematol. 1991;63:259–263
  67. Ohnishi K, Ohno R, Tomonaga M, et al.  A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906–916
  68. Oka T, Sastry KJ, Nehete P, et al.  Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998;12:155–163
  69. Ozer H, George SL, Schiffer CA, et al.  Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood. 1993;10:2975–2984
  70. Pane F, Mostarda I, Selleri C, et al.  BCR/ABL mRNA and the P210BRC/ABL protein are downmodulated by interferon-α in chronic myeloid leukemia patients. Blood. 1999;7:2200–2207
  71. Pigneux A, Faberes C, Boiron JM, et al.  Autologous stem cell transplantation in chronic myeloid leukemia: A single center experience. Bone Marrow Transplant. 1999;24:265–270
  72. Sacchi S, Kantarjian HM, O'Brien S, et al.  Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia. 1997;11:1610–1616
  73. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330–1340
  74. Schmidt M, Hochhaus A, Nitsche A, et al.  Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood. 2001;97:3648–3650
  75. Schofield JR, Robinson WA, Murphy JR. Low doses of interferon-α are as effective as higher doses in inducing remission and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736–744
  76. Shepherd P, Richards S, Allan N. Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-α versus chemotherapy: No significant adverse effect of prolonged IFN-α administration. Blood. 1995;86(suppl 1, abstr 363):94a
  77. Shepherd P, Kluin-Nelemans N, Richards S, et al.  A randomised comparison of low or high dose IFN-α in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups. Results of MCR CML V & HOVON 20 trials. Blood. 2001;98(suppl 1, abstr 3034):727a
  78. Silver RT, Woolf SH, Hehlmann R, et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood. 1999;94:1517–1536
  79. Sinclair PB, Nacheva EP, Leversha M, et al.  Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000;95:738–744
  80. Sokal JE, Leong SS, Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer. 1987;59:197–202
  81. Sokal JE, Cox EB, Baccarani M, et al.  Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–799
  82. Spriggs D, Griffin J, Kufe D. Clinical pharmacology of low-dose arabinosyl cytosine. Blood. 1985;65:1087–1089
  83. Steegmann JL, Casado LF, Tomàs JF, et al.  Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:483–488
  84. Talpaz M, McCredie KB, Mavligit GM, et al.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62:689–692
  85. Talpaz M, Kantarjian HM, McCredie K, et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–1069
  86. Talpaz M, Kantarjian H, Kurzock R, et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532–538
  87. Tomás JF, López-Lorenzo JL, Requena MJ, et al.  Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 1998;22:47–51
  88. Upadhyaya G, Guba SC, Sih SA, et al.  Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 1991;88:2131–2136
  89. Zuffa E, Bandini G, Bonini A, et al.  Prior treatment with α-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica. 1998;83:231–236

☆ Supported in part by a grant from the Italian Ministry of University and the University of Bologna (COFIN 1999 and 2001).

☆☆ Address reprint requests to Michele Baccarani, MD, Institute of Hematology and Medical Oncology “L. and A. Seràgnoli,” S.Orsola Hospital, Via Massarenti 9, 40138 Bologna, Italy.

PII: S0037-1963(03)70040-7

Seminars in Hematology
Volume 40, Issue 1 , Pages 22-33 , January 2003

Article Tools

* Image Usage & Resolution